Bcl9L Antibody

CATALOG NUMBER: 6213

Specifications

SPECIES REACTIVITY: Human
HOMOLOGY: Predicted species reactivity based on immunogen sequence: Mouse: (100%)
TESTED APPLICATIONS: ELISA, ICC, IF, IHC-P, WB
APPLICATIONS: Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 ug/mL. Antibody can also be used for immunohistochemistry starting at 5 ug/mL and immunocytochemistry starting at 10 ug/mL. For immunofluorescence start at 20 ug/mL.
USER NOTE: Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL: 1) Cat. No. 1201 - HeLa Cell Lysate
PREDICTED MOLECULAR WEIGHT: Predicted: 165 kDa
Observed: 195 kDa
SPECIFICITY: Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.
IMMUNOGEN: Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.
The immunogen is located within amino acids 20 - 70 of Bcl9L.
HOST SPECIES: Rabbit
### Properties

**PURIFICATION:** Bcl9L Antibody is affinity chromatography purified via peptide column.

**PHYSICAL STATE:** Liquid

**BUFFER:** Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.

**CONCENTRATION:** 1 mg/mL

**STORAGE CONDITIONS:** Bcl9L antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

**CLONALITY:** Polyclonal

**ISOTYPE:** IgG

**CONJUGATE:** Unconjugated

### Additional Info

**ALTERNATE NAMES:** Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein

**ACCESSION NO.:** NP_872363

**PROTEIN GI NO.:** 32699936

**OFFICIAL SYMBOL:** BCL9L

**GENE ID:** 283149

### Background

**BACKGROUND:** Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wntmediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

**REFERENCES:**


---

FOR RESEARCH USE ONLY

December 12, 2016